Company Market Research Report: Mana.bio
Company Overview
Name, Mission of the Company
Name: Mana.bio
Mission: Mana.bio aims to disrupt the drug delivery space by leveraging the combined forces of machine learning and nanotechnology. The company focuses on gene therapy, including DNA and RNA-based therapeutics, and vaccines.
Founding Information
Founded By: No information is available
Year Founded: No information is available
Key People in the Company
Co-Founder & CEO: Yogev Debbi
- Repeat biotech entrepreneur with experience in business leadership and applying software technologies in biology.
Co-Founder & CTO: Roy Nevo
- Veteran software architect and biotech entrepreneur skilled at leading innovative biotech products.
Scientific Co-Founder: Prof. Avi Schroeder
- Tenured Professor in the Chemical Engineering faculty at the Technion, expert in nanomedicine and drug delivery.
Scientific Co-Founder: Dr. Kira Radinsky
- AI and data science expert focusing on predictive data mining and its applications in medicine.
Advisory Board Members
Cory Sago, PhD: Biomedical engineer and serial entrepreneur specialized in lipid nanoparticles for RNA delivery.
Peter Nell, PhD: Biopharma executive with over 20 years of experience in gene editing from R&D to commercialization.
Gaurav Sahay, PhD: Expert in nanotechnology-based platforms for mRNA therapeutics focused on cystic fibrosis and retinal degeneration.
Barry Ticho, MD PhD: Experienced clinician and drug developer with expertise in neurology and cardiology.
Prof. Eitan Kerem, MD: Pediatric specialist and researcher with notable contributions to cystic fibrosis patient care.
Prof. Jordan Green: Biomedical engineer and entrepreneur developing genetic medicines and immunotherapies.
Lubo Nechev, PhD: Renowned expert in RNAi therapeutics and lipid nanoparticle formulation.
Headquarters
Location: No information is available
Number of Employees
No information is available
Company Revenue
No information is available
Company Reputation
Mana.bio is recognized for its innovative AI-driven approach to developing novel lipid nanoparticle (LNP) formulations for gene therapy and moving beyond traditional limitations in drug delivery.
Products
Core Technologies and Products
1. Lipid Nanoparticle Drug Delivery Systems
- High-Level Description: Mana.bio uses AI and machine learning to design novel LNP formulations tailored for the extrahepatic delivery of nucleic acid therapeutics and vaccines.
- Key Features:
- AI-driven in silico design for predicting desirable properties.
- High-throughput capabilities for synthesizing and creating multiple LNP formulations weekly.
- Automated, high-throughput screening infrastructure to analyze efficacy, safety, and physicochemical properties.
- Continuous improvement of machine learning models using experimental results and publicly available data.
Recent Developments
New Partnerships and Recognitions
- August 6, 2024: Mana.bio was named among the top 20 most promising startups by TheMarker.
- March 25, 2024: Joined NVIDIA Inception program to drive AI innovation and enhance RNA delivery technologies.
- February 28, 2024: Partnership with Ginkgo Bioworks to leverage integrated R&D capabilities.
Funding and Financial Developments
- October 10, 2023: Closed an oversubscribed $19.5M seed funding to advance their AI platform for discovering customizable LNPs.
Technological Advancements
- June 21, 2022: Integrated CAS chemical substance data into its AI platform for a 70% reduction in molecular data acquisition and preparation resources.
Press Coverage and Interviews
- May 14, 2024: CEO Yogev Debbi and Dr. Barry Ticho were featured in the Raising Biotech podcast discussing Mana.bio’s origin and challenges.
- October 10, 2023: Exclusive coverage on using AI to design lipid nanoparticles that go beyond liver delivery.
Conclusion
Mana.bio leverages cutting-edge AI and nanotechnology to design innovative LNP systems for the targeted delivery of nucleic acid therapeutics and vaccines. With a strong leadership team, a robust advisory board, prestigious recognitions, and significant funding, the company is positioned to make substantial advancements in the biotech and pharmaceutical industries.
